Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

PURPOSE: The objective of the present study was to evaluate the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated, in Spain. METHODS: A pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Presa, María, Vicente, David, Calles, Antonio, Salinas-Ortega, Laura, Naik, Jaesh, García, Luis F, Soto, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494862/
https://www.ncbi.nlm.nih.gov/pubmed/37701861
http://dx.doi.org/10.2147/CEOR.S415711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494862/
https://www.ncbi.nlm.nih.gov/pubmed/37701861
http://dx.doi.org/10.2147/CEOR.S415711

Ejemplares similares